Liquidia Corporation

Good morning and welcome everyone to the Liquidia Corporation second quarter 2022 financial results and corporate update conference call. My name is Angela and I'll be your conference operator today. Currently all participants are in a listen only mode. Following the presentation we will conduct a question and answer session. Instructions will be provided at this time for you to queue up for questions. If anyone has any difficulties hearing the conference, please press star zero for operator assistance at any time. I would like to remind everyone that the conference call is being recorded. I will now hand the call over to Jason Adair, Senior Vice President, Corporate Development and Strategy.

Thank you, Angela. It is my pleasure to welcome everyone to Liquidia's second quarter 2022 Financial Results and Corporate Update Conference Call. Joining the call today are Chief Executive Officer Roger Jeffs, Chief Medical Officer Dr. Rajiv Sagar, General Counsel Rusty Schundler, Chief Financial Officer Mike Cassetta, and other members of Quidia Management. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results or performance to be materially different from any future results or performance expressed or implied on this call. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I would now like to turn the call over to Roger for our prepared remarks, after which he will open up the call for your questions.

Thank you, Jason, and good morning, everyone. Over the last three months, we've continued to gain momentum across all areas of the company as we build towards our primary objective of preparing for the potential launch of Utrepia, an inhaled dry powder formulation of Traprocinil. I'll share just a few examples of our progress. In the marketplace, we continue to build the awareness and reputation of Liquidia amongst key stakeholders involved in delivering treatments for the AH, while also increasing utilization of Traprocinil injections. In the clinical arena, we published data from the completed INSPIRE trial in the Journal of Pulmonary Circulation, which validates the enduring value and therapeutic potential for eutropia to be a game changer for PAH patients. In the regulatory area, the FDA confirmed that no additional studies will be required to seek label expansion to treat patients with PHILD in March 2024. In legal forums, we advanced down the path towards Utrepia's final approval with the PTAB in validating all claims of the 793 patent. On the balance sheet, we continue to build for launch while being efficient with our use of capital. And inside the company, we continue to build a high-performing culture, hiring key people to enable both near and long-term success of our products and pipeline. Speaking of hires, I want to introduce you to one of our key new hires, our new chief medical officer, Dr. Rajiv Sagar. Rajiv and I have known each other for years, and he's always impressed me with his determination to make a difference in patients' lives. When I saw the opportunity to include him on our team, I took it immediately. Rajiv brings a strength of knowledge, experience, and curiosity that will help take Liquidia to the next level. Since most of our investors have not had the chance to meet Rajiv, I've asked him to share his impressions so far. Rajiv?